Literature DB >> 11871482

Clinical and epidemiological aspects of Chagas disease.

A Prata1.   

Abstract

Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. During the past decades, after urban migrations, Chagas disease became frequent in cities and a health problem in non-endemic countries, where it can be transmitted vertically and by blood transfusion or organ transplantation. Microepidemics of acute Chagas disease have been reported, probably due to oral transmission. Heart involvement is the major feature of the disease because of its characteristics, frequency, and consequences, and is also the source of most controversies. The indeterminate clinical form, despite its good prognosis on at least a medium-term basis (5-10 years), has acquired increasing importance due to the controversial meaning of the abnormality of some tests and the myocardial focal lesions found in many patients. Simultaneous evaluation of the parasympathetic and of the sympathetic system in the heart has been done by spectral analysis of heart rate. The physiopathological and clinical significance of denervation in Chagas disease is still incompletely understood. There are major divergences of opinion on specific treatment during the chronic phase because of the doubts about cure rates. Changes of Chagas disease prevalence in many countries have been certified by the Pan American Health Organization, and are ascribed to large-scale vector-control programmes with modern pyrethroid insecticides and to improvement in lifestyle.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11871482     DOI: 10.1016/S1473-3099(01)00065-2

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  225 in total

1.  Clinical aspects of Chagas disease and implications for novel therapies.

Authors:  Cristiane Menezes; Germano Carneiro Costa; Kenneth J Gollob; Walderez O Dutra
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

2.  Rapid detection of Trypanosoma cruzi in human serum by use of an immunochromatographic dipstick test.

Authors:  Richard Reithinger; Mario J Grijalva; Rosa F Chiriboga; Belkisyolé Alarcón de Noya; Jaime R Torres; Norma Pavia-Ruz; Pablo Manrique-Saide; Marta V Cardinal; Ricardo E Gürtler
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

Review 3.  Chagas disease and transfusion medicine: a perspective from non-endemic countries.

Authors:  Andrea Angheben; Lucia Boix; Dora Buonfrate; Federico Gobbi; Zeno Bisoffi; Simonetta Pupella; Giorgio Gandini; Giuseppe Aprili
Journal:  Blood Transfus       Date:  2015-10       Impact factor: 3.443

Review 4.  Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.

Authors:  Jacob J Elmer; Matthew D Christensen; Kaushal Rege
Journal:  J Control Release       Date:  2013-08-30       Impact factor: 9.776

5.  Use of an immunochromatographic dipstick test for rapid detection of Trypanosoma cruzi in sera from animal reservoir hosts.

Authors:  Marta V Cardinal; Richard Reithinger; Ricardo E Gürtler
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

6.  Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth.

Authors:  Yuliya V Mishina; Sanjeev Krishna; Richard K Haynes; John C Meade
Journal:  Antimicrob Agents Chemother       Date:  2007-03-05       Impact factor: 5.191

7.  Neurochemical coding of the enteric nervous system in chagasic patients with megacolon.

Authors:  A B M da Silveira; D D'Avila Reis; E C de Oliveira; S G Neto; A O Luquetti; D Poole; R Correa-Oliveira; J B Furness
Journal:  Dig Dis Sci       Date:  2007-03-24       Impact factor: 3.199

Review 8.  Bone marrow-derived cell therapy in chagasic cardiac disease: a review of pre-clinical and clinical results.

Authors:  Antonio Carlos Campos de Carvalho; Adriana Bastos Carvalho; Debora Bastos Mello; Regina Coeli Dos Santos Goldenberg
Journal:  Cardiovasc Diagn Ther       Date:  2012-09

9.  Trypanosoma cruzi 13C-labeled O-Glycan standards for mass spectrometry.

Authors:  M Osman Sheikh; Elisabet Gas-Pascual; John N Glushka; Juan M Bustamante; Lance Wells; Christopher M West
Journal:  Glycobiology       Date:  2019-04-01       Impact factor: 4.313

10.  Chagasic cardiomyopathy and Pompe disease: case report.

Authors:  Rafael Ob de Morais; Ândrea V Chaves-Markman; Anna Pp Miranda; Ingrid G Amorim; Maria da Ga de M Cavalcanti; Manuel Markman; Brivaldo Markman-Filho
Journal:  Am J Cardiovasc Dis       Date:  2018-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.